Treatment Registry
TR-0644 ActiveRecorded September 2026

Compounded tirzepatide

Sold by DadVantage · Injection, vial · every compounded tirzepatide record

Price

TermPublished rateCharged today
Tirzepatide / Niacinamide, 2.5mg/week, 8 weeks

“Tirzepatide / Niacinamide Injection 2.5mg/week: $400: 8 weeks”

$400Per 8 weeksCharged today$400
Tirzepatide / Niacinamide, 5mg/week, 12 weeks (save $200)

“5mg/week: $700: 6 weeks | $1,200: 12 weeks (Save $200)”

$1,200Per 12 weeksCharged today$1,200
Tirzepatide / Niacinamide, 2.5mg/week, 16 weeks (save $100)

“$700: 16 weeks (Save $100)”

$700Per 16 weeksCharged today$700
Price sources
Visit DadVantage

We earn nothing from this link. It opens DadVantage's website without a paid referral.

History

Fewer than two comparable calendar-month readings are available for a price trend. Day- or week-based supplies, introductory offers and unverified payment terms are not connected in this chart.

  • September 2026 — Entry added to the register

Sourcing and terms

PrescriberLive visit
CancellationNo insurance games. No hidden fees. Every cost is on this page. Cancel anytime: no penalties, no questions.
MembershipRequired. $50 per month. Weight Loss Optimization Follow-Ups $50/month subscription. Includes weekly self-injections/orals, monthly follow-ups, plan adjustments, diet/exercise coaching, and direct provider access. Medication costs separate.

Not yet checked: pharmacy, states and consult fee.

Recorded from dadvantagemenshealth.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.

Notes

  1. 1. September 2026 — The itemized Semaglutide/B12 and Tirzepatide/Niacinamide medication prices are quoted in weeks on the page; term/perMonth above are converted assuming ~4.33 weeks/month, same convention used elsewhere in this project. A separate $17,995/year 'Weight Loss Executive Bundle (GLP-1)' also exists but doesn't specify semaglutide vs. tirzepatide, so it isn't broken into a price entry here.

Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.

This record

Entry
TR-0644
Medication category
compounded tirzepatide
Readings
1

Related records

Cite this entry

Treatment Registry. (2026). DadVantage — compounded tirzepatide (TR-0644). Last verified September 2026. Retrieved [your access date], from https://treatmentregistry.com/registry/TR-0644

Replace the bracket with the date you read it. Ours is the date we last checked the figures, which is a different thing and is given separately.